Erasca (NASDAQ:ERAS) Shares Down 10.6% – Here’s What Happened

Erasca, Inc. (NASDAQ:ERAS) shares dropped 10.6% during trading on Thursday . The company traded as low as $18.98 and last traded at $19.0050. 4,325,016 shares were traded during trading, a decline of 35% from the average daily volume of 6,631,624 shares. The stock had previously closed at $21.26.

Key Erasca News

Here are the key news stories impacting Erasca this week:

• Positive Sentiment: Erasca announced updated preliminary Phase 1 data and registration-enabling plans for ERAS-0015, which helped renew optimism around the program’s clinical potential. Article Title
• Positive Sentiment: Bank of America reportedly raised its price target on Erasca to $18, suggesting some analysts see value after the recent volatility. Article Title
• Neutral Sentiment: Erasca closed an upsized public offering of 36.1 million shares at $17.50 per share, raising about $632.5 million to fund its oncology pipeline. Article Title
• Negative Sentiment: Investors are being reminded of the securities class action alleging Erasca misled the market about ERAS-0015, including patent and patient-safety risks, which keeps legal overhang front and center. Article Title
• Negative Sentiment: Several plaintiff-law-firm notices about the upcoming deadline may add to near-term selling pressure by amplifying concerns about possible damages and litigation costs. Article Title

Analysts Set New Price Targets

A number of research firms have recently issued reports on ERAS. Mizuho lowered their target price on Erasca from $28.00 to $26.00 and set an “outperform” rating for the company in a research note on Tuesday, May 12th. JPMorgan Chase & Co. boosted their price target on Erasca from $24.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 18th. Wolfe Research set a $16.00 price target on Erasca in a report on Thursday, June 4th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Erasca in a research report on Tuesday. Finally, HC Wainwright reiterated a “buy” rating on shares of Erasca in a research note on Tuesday. Eight equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Erasca currently has an average rating of “Moderate Buy” and a consensus price target of $20.64.

Erasca Trading Down 10.9%

The business’s 50-day simple moving average is $14.20 and its two-hundred day simple moving average is $13.22. The company has a market capitalization of $5.89 billion, a PE ratio of -20.29 and a beta of 0.66.

Erasca (NASDAQ:ERAS) last announced its earnings results on Monday, May 11th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.48). On average, analysts forecast that Erasca, Inc. will post -0.55 EPS for the current year.

Institutional Investors Weigh In On Erasca

Hedge funds and other institutional investors have recently bought and sold shares of the business. VR Adviser LLC raised its holdings in Erasca by 10.1% in the second quarter. VR Adviser LLC now owns 17,857,083 shares of the company’s stock valued at $22,678,000 after acquiring an additional 1,640,867 shares in the last quarter. Paradigm Biocapital Advisors LP boosted its stake in Erasca by 4.4% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 14,159,095 shares of the company’s stock valued at $52,672,000 after acquiring an additional 599,078 shares during the period. Vanguard Group Inc. boosted its position in Erasca by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 12,811,832 shares of the company’s stock valued at $27,930,000 after purchasing an additional 116,235 shares during the period. Vivo Capital LLC grew its position in shares of Erasca by 31.0% during the first quarter. Vivo Capital LLC now owns 12,151,480 shares of the company’s stock worth $196,611,000 after acquiring an additional 2,878,052 shares during the last quarter. Finally, Siren L.L.C. increased its stake in shares of Erasca by 28.4% in the first quarter. Siren L.L.C. now owns 11,244,246 shares of the company’s stock valued at $181,932,000 after purchasing an additional 2,486,997 shares during the period. 67.78% of the stock is currently owned by hedge funds and other institutional investors.

Erasca Company Profile

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.